Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial (LIBERTY AD ADOL)

Main Article Content

Lawrence Sher
Weily Soong
Randy Prescilla
Zhen Chen
Ashish Bansal

Keywords

Atopic Dermatitis, Biologics, Dupilumab, Atopy, Allergic Rhinitis

Abstract

Abstract not available.

References

1. Shrestha S, et al. Adv Ther. 2017;34:1989-2006.

2. Silverberg JI, Simpson EL. Pediatr Allergy Immunol. 2013;24:476-86.

3. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35-50.

4. Thaçi et al. J Allergy Clin Immunol. 2018;141 Suppl:AB136. Data presented at 2018 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress; Orlando, FL, USA; March 2–5, 2018; poster P430.

5. Simpson EL, et al. JAMA Dermatol. 2019 Nov 6 [Epub ahead of print]. doi: https://doi.org/10.1001/jamadermatol.2019.3336

6. Prens E, et al. Allergy. 2018;73(S105):3-115 AB0140. Data presented at 2018 European Academy of Allergy and Clinical Immunology (EAACI); Munich, Germany; May 26–30, 2018; oral presentation and poster.

Article Sidebar

Poster PDF
Published
Sep 2, 2020
DOI https://doi.org/10.25251/skin.4.supp.50

Article Details

How to Cite
Sher, L., Soong, W., Prescilla, R., Chen, Z., & Bansal, A. (2020). Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial (LIBERTY AD ADOL). SKIN The Journal of Cutaneous Medicine, 4(5), s51. https://doi.org/10.25251/skin.4.supp.50
Issue
Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.